drugset / Trial / NCT04771130
A Study of BGB-11417 in Participants With Myeloid Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Timeline
- Start
- 2021-05-24
- Primary completion
- 2028-02-08
- Completion
- 2028-02-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Intravenous |
| Subject | Posaconazole | Small molecule | — | Oral |
| Subject | Sonrotoclax | Other / unclassified | — | Oral |